Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology company that is reshaping the landscape of cancer treatment through its proprietary INTASYL siRNA gene silencing technology. As a company focused on immuno-oncology therapeutics, Phio is dedicated to improving the ability of the body’s immune cells to target and eliminate tumor cells. Backed by rigorous scientific research and collaborative partnerships with leading research institutions, the company is committed to advancing next-generation treatments that address the immune suppression often induced by tumors.
Core Technology and Therapeutic Approach
The cornerstone of Phio Pharmaceuticals’ approach is its INTASYL platform, a unique self-delivering RNAi technology that bypasses the conventional need for specialized drug delivery systems. Unlike other RNAi therapies, INTASYL can target virtually any gene with high specificity, ensuring that immune cells are better equipped to kill cancer cells without impacting non-harmful cells. This innovative technology is specifically designed to silence genes responsible for tumor-induced immune suppression, thereby enhancing the efficacy of adoptive cell therapy as well as other immuno-oncology treatments.
Clinical-Stage Programs and Product Pipeline
Phio’s product development strategy centers on a portfolio of therapeutics that leverage INTASYL to selectively silence key checkpoint proteins. Its lead clinical program, PH-762, is an INTASYL compound aimed at silencing PD-1, a protein that inhibits the immune response by dampening T cell activity. This approach offers a potential non-surgical treatment option for various skin cancers such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. In addition, the company is developing other compounds, including ones that target TIGIT and PD-L1, to broaden its impact in the immuno-oncology space.
The ongoing Phase 1b clinical trials utilize an intratumoral injection strategy, which not only provides localized treatment but also enhances the immune system's ability to combat tumors systemically. The safety and efficacy profiles observed in early cohorts underscore the potential of Phio’s approach, with early clinical data emphasizing tumor clearance in patients while maintaining a manageable safety profile.
Scientific Collaborations and Research Excellence
Phio Pharmaceuticals collaborates with renowned institutions across the globe, including partnerships with collaborative research centers and academic institutions. These collaborations, with entities like Gustave Roussy, Medigene AG, and Helmholtz Zentrum, underscore the company’s commitment to scientific excellence and innovation. Working jointly with experts in immunology and oncology, Phio benefits from access to advanced research methodologies and clinical expertise, further solidifying its position as an innovator in the RNAi and immuno-oncology domains.
Market Position and Competitive Landscape
Operating within the competitive realm of biotechnology and cancer therapeutics, Phio Pharmaceuticals distinguishes itself by leveraging a novel technology platform that integrates precision medicine with the power of the immune system. The ability of the INTASYL platform to effectively silence genes without the need for extensive formulation upgrades positions the company uniquely amongst peers and potential collaborators. This technological edge is particularly significant in the context of adoptive cell therapy, where streamlined delivery and strong gene specificity are critical for success.
Technological Advantages of INTASYL
The INTASYL siRNA technology offers several key advantages:
- Self-Delivery: Eliminates the need for complex delivery vehicles, reducing development hurdles and potential complications.
- High Specificity: Capable of silencing target genes with a high degree of precision across a wide range of cell types, thereby mitigating off-target effects.
- Versatility: The platform’s ability to target virtually any gene affords tremendous flexibility in addressing various pathways associated with tumor immune suppression.
- Enhanced Immune Function: By targeting immunosuppressive proteins, Phio’s therapies aim to activate and bolster the body's natural defenses against cancer cells.
Understanding the Business Model
Phio Pharmaceuticals generates value by advancing its clinical-stage pipeline through strategic investments in research and development, clinical trials, and collaborations with academic and research centers. While the company is primarily in the research and development phase, its focus on breakthrough technologies and innovative therapeutic approaches forms the backbone of its long-term strategy. By maintaining a diversified pipeline that targets multiple immune regulatory pathways, Phio effectively manages scientific risk while paving the way for potential future therapies that address the multifaceted challenges of cancer treatment.
Commitment to Scientific Rigor and Transparency
In its quest to provide a thorough understanding of its technologies and clinical developments, Phio Pharmaceuticals embraces a transparent approach to research and data reporting. The company regularly presents data at industry conferences and in peer-reviewed journals, thereby contributing to the broader scientific community’s understanding of RNAi and immuno-oncology. This commitment to transparency not only enhances its credibility among investors and researchers but also underscores the company’s dedication to advancing scientific knowledge in a challenging and dynamic field.
Conclusion
Phio Pharmaceuticals Corp stands at the intersection of innovation and clinical research, leveraging a unique self-delivering RNAi technology to address the unmet needs in cancer therapy. Its comprehensive approach, which combines precision gene silencing with enhanced immune cell activity, positions it as a notable participant in the biotechnology arena. By continuously advancing its clinical programs and forging strategic collaborations, Phio demonstrates a firm commitment to improving patient outcomes through cutting-edge science and technology.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its CEO, Dr. Gerrit Dispersyn, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9, and can be accessed through the company's website. Phio is focused on advancing its proprietary self-delivering RNAi therapeutic platform, INTASYL™, aimed at treating cancer by enhancing immune response against tumor cells.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has successfully completed a registered direct offering of 2,246,784 shares of common stock at $3.42 per share, yielding gross proceeds of approximately $7.7 million. The funds will primarily support working capital needs and the advancement of its immuno-oncology programs. The offering was conducted under a shelf registration statement declared effective by the SEC in 2018. H.C. Wainwright & Co. served as the placement agent for this offering.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced a registered direct offering of 2,246,784 shares of common stock priced at $3.42 per share, raising approximately $7.7 million. The offering is expected to close around February 17, 2021, pending customary closing conditions. The funds will primarily support general working capital, including the development of immuno-oncology programs. H.C. Wainwright & Co. serves as the exclusive placement agent. The shares are offered under an effective shelf registration statement.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the closing of a private placement, issuing 4,560,928 shares at $3.07 each, alongside warrants for 3,420,696 shares. This transaction raised approximately $14.0 million before expenses. The company plans to use the funds for its immuno-oncology research and general working capital. The warrants have an exercise price of $3.00 and are valid for five and a half years. Phio must file a registration statement covering the resale of the shares by February 1, 2021.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced a private placement to raise approximately $14.0 million by issuing 4,560,928 shares of common stock at $3.07 per share, along with warrants for 3,420,693 shares at an exercise price of $3.00. The placement is expected to close around January 25, 2021. Proceeds will be used for the development of immuno-oncology programs and general working capital. The company is required to file a registration statement within ten days for the resale of shares issued to investors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Dr. Gerrit Dispersyn's corporate presentation will be available on-demand starting at 6 a.m. ET on January 11, 2021. The webcast can be accessed through the Company’s website and will be archived for 90 days. Phio focuses on advancing immuno-oncology therapeutics using its self-delivering RNAi platform, INTASYL™, aimed at tackling tumor-induced immune suppression.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology firm focused on immuno-oncology, announced that CEO Dr. Gerrit Dispersyn will present at the 3rd Annual Evercore ISI HealthCONx Conference, held virtually from December 1-3, 2020. Dr. Dispersyn's fireside chat is scheduled for December 3 at 3:05 p.m. ET, accessible via a live webcast. Phio's proprietary INTASYL™ RNAi platform aims to enhance immune responses against tumors. More details and a recorded version will be available on the company’s website post-event.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q3 2020, ending with $16.9 million in cash, up from $6.9 million in December 2019. The company increased R&D expenses to $1.3 million, attributed to preclinical studies. The net loss for the quarter was $2.3 million, or $0.40 per share, slightly higher than the $2.1 million net loss from the same quarter last year. Phio presented promising data at SITC 2020, showcasing its INTASYL RNAi technology's potential in enhancing cancer immunotherapy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising results from a recent in vivo study demonstrating the enhanced efficacy of its INTASYL pipeline products when combined. The data, presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, shows that combining INTASYL compounds significantly improves tumor control compared to monotherapy. The compounds target PD-1, PD-L1, and TIGIT proteins linked to immune suppression in cancer. These findings suggest a potential breakthrough in the treatment of solid tumors, increasing the therapeutic options available for patients.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced three upcoming poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), occurring virtually from November 9-14, 2020. The poster presentations highlight INTASYL compounds, a proprietary self-delivering RNAi therapeutic platform. Notably, findings include a study on combination treatment using INTASYL targeting TIGIT and PD-1/PD-L1, revealing enhanced tumor control. The archived presentation will be accessible in the "Investors – Events and Presentations" section of the Company's website.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What is the primary focus of Phio Pharmaceuticals Corp?
How does the INTASYL technology work?
Which therapeutic targets are addressed by Phio's pipeline?
What clinical trials is Phio currently engaged in?
How does Phio position itself within the competitive biotech industry?
What are the advantages of the INTASYL platform?
Who are some of Phio's research collaborators?
What role does PH-762 play in Phio's clinical program?
